Page 11 of 62: studies 101 to 110 of 613, newest first. Back to the ibogaine overview
Zenodo (CERN European Organization for Nuclear Research) 2023 Dalibor Sames preprint
Dalibor Sameš - Ibogaine: An Update (psychedelic molecules, 4th-5th September 2023, Prague, Czech Republic)
Frontiers in Pain Research 2023 Jonathan Dickinson, Jose Adalberto Dominguez Inzunza, Liliana Perez-Villa et al. 3 citations
Brachial plexus nerve root avulsion results from complete separation of the nerve root from the spinal cord and is one of the most challenging types of neuropathic pain, coinciding with motor, sensory and autonomic deficits. The severe pain and typical impossibility of root reattachment often leads to requests for amputation. Ibogaine is an indole alkaloid producing psychoactive effects through...
Current Neuropharmacology October 20, 2022 Alessio Mosca, Stefania Chiappini, Andrea Miuli et al. 30 citations
BACKGROUND: Ibogaine and noribogaine are psychedelic substances with dissociative properties naturally occurring in plants of the Apocynaceae family. Research has shown their efficacy in treating substance use disorders (SUD), particularly in opiate detoxification, but their efficacy and toxicity are still unclear. OBJECTIVE: This review aims to assess the anti-addictive role of ibogaine and...
Health Psychology Research October 6, 2022 Amber N. Edinoff, Natalie W. Wu, Bryce Bonin et al. 11 citations
Even as prescription opioid dispensing rates have begun to decrease, the use of illicit opioids such as heroin and fentanyl has increased. Thus, the end of the opioid epidemic is not in sight, and treating patients that are addicted to opioids remains of utmost importance. Currently, the primary pharmacotherapies used to treat opioid addiction over the long term are the opioid antagonist...
Research Square September 8, 2022 Maria Helha Fernandes-Nascimento, André Brooking Negrão, Karine Viana-Ferreira et al. preprint
Abstract Objective To evaluate the publications on ibogaine use for substance-related disorders treatment over the last three decades. Method Bibliometric analysis of publications on ibogaine for the treatment of substance-related disorders from 1991 to 2020 using VOSviewer software. We performed a Scopus database search using the terms: ibogaine, 12-methoxybogamine, endabuse, tabernanthe...
Anthropology of Consciousness July 8, 2022 Bruno Ramos Gomes, Luís Fernando Tófoli 2 citations
ABSTRACT This research qualitatively investigated four treatments for addiction in Brazil that use ibogaine as the main tool in the process. Ibogaine is a substance derived from an African plant, Tabernanthe iboga, traditionally used in its region of origin and which leads to intense sensations during its acute effects and also different experiences of oneself and the surrounding world in the...
Journal of Substance Abuse Treatment July 1, 2022 Patrick Köck, Katharina Froelich, Marc Walter et al. 68 citations
Iboga and its primary alkaloids, ibogaine and noribogaine, have been of interest to researchers and practitioners, mainly due to their putative efficacy in treating substance use disorders (SUDs). For many SUDs, still no effective pharmacotherapies exist. Distinct psychoactive and somatic effects of the iboga alkaloids set them apart from classic hallucinogens like LSD, mescaline, and...
Brain and Neurological Disorders June 21, 2022 Abdul Wahab Alahmari
Many psychedelics drugs are praised on social media platforms like YouTube by non-experts or bias documentaries claiming that these drugs have therapeutic effects on addicted patients or clarity of the mind. The aim of this paper is to collect a neuroimaging documentation of these psychedelics’ drugs and their effect on the brain. That can be documented on MRI, CT, or any other imaging modalities.
Psychopharmacology June 1, 2022 Genís Ona, Juliana Mendes Rocha, José Carlos Bouso et al. 41 citations
Ibogaine is the main alkaloid of the African shrub Tabernanthe iboga. It produces hallucinogenic and psychostimulant effects, but it is currently known for the anti-addictive properties. Despite the potential therapeutic effects, several cases of fatalities and serious adverse events related to ibogaine/noribogaine use can be found in the literature. Most studies consist in case reports or were...
ACS Medicinal Chemistry Letters May 26, 2022
ADVERTISEMENT RETURN TO ISSUEPREVPatent HighlightNEXTIbogaine and Their Analogs as Therapeutics for Neurological and Psychiatric DisordersRobert B. Kargbo*Robert B. KargboUsona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States*[email protected]More by Robert B. Kargbohttps://orcid.org/0000-0002-5539-6343Cite this: ACS Med. Chem. Lett. 2022, 13, 6,...